Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -61.53% is 29% below its 1-year average of -47.53%, near the low end of its 1-year range (-61.53%–-33.53%).
As of the fiscal period ended Wednesday, December 31, 2025. 29.46% below its 12-month average of -47.53%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.97%.
RETURN ON ASSETS (ROA)
-61.53%
RETURN ON ASSETS (ROA) AVG TTM
-47.53%
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-29.46%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.70%
median of 715 covered companies
CURRENT VS SECTOR MEDIAN
-100.42%
vs the sector median at left
Generate Biomedicines, Inc.
Market Cap
$1.79B
Return on Assets (ROA)
-61.53%
TTM Avg
-47.53%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.82B
Return on Assets (ROA)
10.25%
TTM Avg
8.68%
3Y Avg
8.17%
5Y Avg
8.38%
Market Cap
$1.83B
Return on Assets (ROA)
-45.02%
TTM Avg
-50.76%
3Y Avg
-46.27%
5Y Avg
-37.50%
Market Cap
$1.83B
Return on Assets (ROA)
-18.68%
TTM Avg
-15.27%
3Y Avg
-14.09%
5Y Avg
-9.93%
Market Cap
$1.84B
Return on Assets (ROA)
1.78%
TTM Avg
2.10%
3Y Avg
3.84%
5Y Avg
3.40%
Market Cap
$1.74B
Return on Assets (ROA)
3.18%
TTM Avg
-8.22%
3Y Avg
-16.26%
5Y Avg
-17.13%
Market Cap
$1.72B
Return on Assets (ROA)
-46.66%
TTM Avg
-46.30%
3Y Avg
-40.19%
5Y Avg
-33.55%
Market Cap
$1.86B
Return on Assets (ROA)
-24.34%
TTM Avg
-44.90%
3Y Avg
-10.89%
5Y Avg
-12.22%
Market Cap
$1.72B
Return on Assets (ROA)
-10.49%
TTM Avg
-13.41%
3Y Avg
-10.26%
5Y Avg
-6.23%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Generate Biomedicines, Inc. (GENB) | $1.79B | -61.53% | -47.53% | N/A | N/A |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 10.25% | 8.68% | 8.17% | 8.38% |
| Absci Corporation (ABSI)vs › | $1.83B | -45.02% | -50.76% | -46.27% | -37.50% |
| Novocure Ltd (NVCR)vs › | $1.83B | -18.68% | -15.27% | -14.09% | -9.93% |
| Astrana Health, Inc. (ASTH)vs › | $1.84B | 1.78% | 2.10% | 3.84% | 3.40% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 3.18% | -8.22% | -16.26% | -17.13% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | -46.66% | -46.30% | -40.19% | -33.55% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.86B | -24.34% | -44.90% | -10.89% | -12.22% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.72B | -10.49% | -13.41% | -10.26% | -6.23% |
| Novavax, Inc. (NVAX)vs › | $1.85B | -25.92% | 12.70% | -8.51% | -21.36% |
ROA
-61.5%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -61.53% |
| 2024-12-31 | -33.53% |
